|
|
罗沙司他治疗肾性贫血的研究进展
|
Abstract:
近年来，肾性贫血的治疗取得了重大进展。罗沙司他作为全球首个获批的缺氧诱导因子脯氨酰羟化酶抑制剂(HIF-PHI)，可模拟缺氧状态以稳定HIF-α亚基，从而激活内源性促红细胞生成素(EPO)的合成，并改善铁代谢。这为肾性贫血提供了一种全新的治疗策略。然而，其长期安全性以及HIF通路多靶点效应的潜在影响仍有待进一步验证。本综述旨在探讨罗沙司他治疗肾性贫血的作用机制、临床证据及其他潜在影响，从而为优化贫血管理提供见解。
In recent years, substantial advancements have been achieved in the treatment of renal anemia. Roxadustat, as the world’s first approved hypoxia-inducible factor prolyl hydroxylase inhibitor (HIF-PHI), mimics hypoxic conditions to stabilize HIF-α subunits, thereby activating endogenous erythropoietin (EPO) synthesis and enhancing iron metabolism. This provides a novel therapeutic strategy for anemia associated with chronic kidney disease (CKD). However, further validation is required regarding its long-term safety and the potential implications of the multi-target effects of the HIF pathway. This review aims to examine the mechanism of action, clinical evidence, and other potential effects of Roxadustat in treating anemia, thereby offering insights for optimizing anemia management.
| [1] | GBD Chronic Kidney Disease Collaboration (2020) Global, Regional, and National Burden of Chronic Kidney Disease, 1990-2017: A Systematic Analysis for the Global Burden of Disease Study 2017. The Lancet, 395, 709-733. |
| [2] | Matsushita, K., Ballew, S.H., Wang, A.Y., Kalyesubula, R., Schaeffner, E. and Agarwal, R. (2022) Epidemiology and Risk of Cardiovascular Disease in Populations with Chronic Kidney Disease. Nature Reviews Nephrology, 18, 696-707. https://doi.org/10.1038/s41581-022-00616-6 |
| [3] | Babitt, J.L. and Lin, H.Y. (2012) Mechanisms of Anemia in CKD. Journal of the American Society of Nephrology, 23, 1631-1634. https://doi.org/10.1681/asn.2011111078 |
| [4] | Fishbane, S. and Coyne, D.W. (2020) How I Treat Renal Anemia. Blood, 136, 783-789. https://doi.org/10.1182/blood.2019004330 |
| [5] | Weir, M.R. (2021) Managing Anemia across the Stages of Kidney Disease in Those Hyporesponsive to Erythropoiesis-Stimulating Agents. American Journal of Nephrology, 52, 450-466. https://doi.org/10.1159/000516901 |
| [6] | Gupta, N. and Wish, J.B. (2017) Hypoxia-Inducible Factor Prolyl Hydroxylase Inhibitors: A Potential New Treatment for Anemia in Patients with CKD. American Journal of Kidney Diseases, 69, 815-826. https://doi.org/10.1053/j.ajkd.2016.12.011 |
| [7] | Abrass, C.K., Hansen, K., Popov, V. and Denisenko, O. (2011) Alterations in Chromatin Are Associated with Increases in Collagen III Expression in Aging Nephropathy. American Journal of Physiology-Renal Physiology, 300, F531-F539. https://doi.org/10.1152/ajprenal.00237.2010 |
| [8] | Souma, T., Nezu, M., Nakano, D., Yamazaki, S., Hirano, I., Sekine, H., et al. (2016) Erythropoietin Synthesis in Renal Myofibroblasts Is Restored by Activation of Hypoxia Signaling. Journal of the American Society of Nephrology, 27, 428-438. https://doi.org/10.1681/asn.2014121184 |
| [9] | Kakinuma, Y., Miyauchi, T., Yuki, K., Murakoshi, N., Goto, K. and Yamaguchi, I. (2001) Novel Molecular Mechanism of Increased Myocardial Endothelin-1 Expression in the Failing Heart Involving the Transcriptional Factor Hypoxia-Inducible Factor-1α Induced for Impaired Myocardial Energy Metabolism. Circulation, 103, 2387-2394. https://doi.org/10.1161/01.cir.103.19.2387 |
| [10] | Ban, H.S., Uto, Y. and Nakamura, H. (2021) Hypoxia-Inducible Factor (HIF) Inhibitors: A Patent Survey (2016-2020). Expert Opinion on Therapeutic Patents, 31, 387-397. https://doi.org/10.1080/13543776.2021.1874345 |
| [11] | Vincent, K.A., Shyu, K., Luo, Y., Magner, M., Tio, R.A., Jiang, C., et al. (2000) Angiogenesis Is Induced in a Rabbit Model of Hindlimb Ischemia by Naked DNA Encoding an Hif-1α/vp16 Hybrid Transcription Factor. Circulation, 102, 2255-2261. https://doi.org/10.1161/01.cir.102.18.2255 |
| [12] | Chen, N., Hao, C., Peng, X., Lin, H., Yin, A., Hao, L., et al. (2019) Roxadustat for Anemia in Patients with Kidney Disease Not Receiving Dialysis. New England Journal of Medicine, 381, 1001-1010. https://doi.org/10.1056/nejmoa1813599 |
| [13] | Del Vecchio, L. and Locatelli, F. (2018) Investigational Hypoxia-Inducible Factor Prolyl Hydroxylase Inhibitors (HIF-PHI) for the Treatment of Anemia Associated with Chronic Kidney Disease. Expert Opinion on Investigational Drugs, 27, 613-621. https://doi.org/10.1080/13543784.2018.1493455 |
| [14] | Jatho, A., Zieseniss, A., Brechtel-Curth, K., Guo, J., Böker, K.O., Salinas, G., et al. (2022) The HIFα-Stabilizing Drug Roxadustat Increases the Number of Renal Epo-Producing Sca-1+ Cells. Cells, 11, Article No. 753. https://doi.org/10.3390/cells11040753 |
| [15] | Rabinowitz, M.H. (2013) Inhibition of Hypoxia-Inducible Factor Prolyl Hydroxylase Domain Oxygen Sensors: Tricking the Body into Mounting Orchestrated Survival and Repair Responses. Journal of Medicinal Chemistry, 56, 9369-9402. https://doi.org/10.1021/jm400386j |
| [16] | Nakai, T., Iwamura, Y., Kato, K., Hirano, I., Matsumoto, Y., Tomioka, Y., et al. (2023) Drugs Activating Hypoxia-Inducible Factors Correct Erythropoiesis and Hepcidin Levels via Renal EPO Induction in Mice. Blood Advances, 7, 3793-3805. https://doi.org/10.1182/bloodadvances.2023009798 |
| [17] | Macdougall, I.C., Bircher, A.J., Eckardt, K.-U., et al. (2016) Iron Management in Chronic Kidney Disease: Conclusions from a “Kidney Disease: Improving Global Outcomes” (KDIGO) Controversies Conference. Kidney International, 89, 28-39. |
| [18] | van der Weerd, N.C., et al. (2015) Hepcidin in Chronic Kidney Disease: Not an Anaemia Management Tool, but Promising as a Cardiovascular Biomarker. The Netherlands Journal of Medicine, 73, 108-118. |
| [19] | Fishbane, S., El-Shahawy, M.A., Pecoits-Filho, R., Van, B.P., Houser, M.T., Frison, L., et al. (2021) Roxadustat for Treating Anemia in Patients with CKD Not on Dialysis: Results from a Randomized Phase 3 Study. Journal of the American Society of Nephrology, 32, 737-755. https://doi.org/10.1681/asn.2020081150 |
| [20] | Provenzano, R., Besarab, A., Sun, C.H., Diamond, S.A., Durham, J.H., Cangiano, J.L., et al. (2016) Oral Hypoxia-Inducible Factor Prolyl Hydroxylase Inhibitor Roxadustat (FG-4592) for the Treatment of Anemia in Patients with CKD. Clinical Journal of the American Society of Nephrology, 11, 982-991. https://doi.org/10.2215/cjn.06890615 |
| [21] | Eliasson, P. and Jönsson, J. (2009) The Hematopoietic Stem Cell Niche: Low in Oxygen but a Nice Place to Be. Journal of Cellular Physiology, 222, 17-22. https://doi.org/10.1002/jcp.21908 |
| [22] | Ke, Q. and Costa, M. (2006) Hypoxia-Inducible Factor-1 (HIF-1). Molecular Pharmacology, 70, 1469-1480. https://doi.org/10.1124/mol.106.027029 |
| [23] | Takada, A., Shibata, T., Shiga, T., Ugawa, T., Komatsu, K. and Akizawa, T. (2022) Pharmacokinetic/Pharmacodynamic Modeling of Roxadustat’s Effect on LDL Cholesterol in Patients in Japan with Dialysis-Dependent Chronic Kidney Disease and Anemia. Drug Metabolism and Pharmacokinetics, 46, Article ID: 100461. https://doi.org/10.1016/j.dmpk.2022.100461 |
| [24] | Fishbane, S., Pollock, C.A., El-Shahawy, M., Escudero, E.T., Rastogi, A., Van, B.P., et al. (2022) Roxadustat versus Epoetin Alfa for Treating Anemia in Patients with Chronic Kidney Disease on Dialysis: Results from the Randomized Phase 3 ROCKIES Study. Journal of the American Society of Nephrology, 33, 850-866. https://doi.org/10.1681/asn.2020111638 |
| [25] | Hirai, K., Kaneko, S., Minato, S., Yanai, K., Hirata, M., Kitano, T., et al. (2023) Effects of Roxadustat on Anemia, Iron Metabolism, and Lipid Metabolism in Patients with Non-Dialysis Chronic Kidney Disease. Frontiers in Medicine, 10, Article ID: 1071342. https://doi.org/10.3389/fmed.2023.1071342 |
| [26] | Zheng, F., Zhang, P., Zhao, M., Wang, J., Xu, X., Zhang, C., et al. (2022) Effect of Roxadustat on Factors Associated with Renal Fibrosis and Efficacy. Computational and Mathematical Methods in Medicine, 2022, Article ID: 4764254. https://doi.org/10.1155/2022/4764254 |
| [27] | Wang, L., Fan, J., Yang, T., Shen, J., Wang, L. and Ge, W. (2024) Investigating the Therapeutic Effects and Mechanisms of Roxadustat on Peritoneal Fibrosis Based on the TGF-β/Smad Pathway. Biochemical and Biophysical Research Communications, 693, Article ID: 149387. https://doi.org/10.1016/j.bbrc.2023.149387 |
| [28] | Eltzschig, H.K. and Carmeliet, P. (2011) Hypoxia and Inflammation. New England Journal of Medicine, 364, 656-665. https://doi.org/10.1056/nejmra0910283 |
| [29] | Eleftheriadis, T., Pissas, G., Mavropoulos, A., Nikolaou, E., Filippidis, G., Liakopoulos, V., et al. (2020) In Mixed Lymphocyte Reaction, the Hypoxia-Inducible Factor Prolyl-Hydroxylase Inhibitor Roxadustat Suppresses Cellular and Humoral Alloimmunity. Archivum Immunologiae et Therapiae Experimentalis, 68, Article No. 31. https://doi.org/10.1007/s00005-020-00596-0 |
| [30] | Semenza, G.L. (2012) Hypoxia-Inducible Factors in Physiology and Medicine. Cell, 148, 399-408. https://doi.org/10.1016/j.cell.2012.01.021 |
| [31] | Zhu, Y., Wang, Y., Jia, Y., Xu, J. and Chai, Y. (2019) Roxadustat Promotes Angiogenesis through HIF-1α/VEGF/VEGFR2 Signaling and Accelerates Cutaneous Wound Healing in Diabetic Rats. Wound Repair and Regeneration, 27, 324-334. https://doi.org/10.1111/wrr.12708 |
| [32] | Huang, L., Chou, H. and Chen, C. (2021) Roxadustat Attenuates Hyperoxia-Induced Lung Injury by Upregulating Proangiogenic Factors in Newborn Mice. Pediatrics & Neonatology, 62, 369-378. https://doi.org/10.1016/j.pedneo.2021.03.012 |
| [33] | Haraguchi, T., Hamamoto, Y., Kuwata, H., Yamazaki, Y., Nakatani, S., Hyo, T., et al. (2023) Effect of Roxadustat on Thyroid Function in Patients with Renal Anemia. The Journal of Clinical Endocrinology & Metabolism, 109, e69-e75. https://doi.org/10.1210/clinem/dgad483 |
